MSD has won the race to bring an oral PCSK9 inhibitor through to regulatory approval in the US, after getting the go-ahead ...

The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...

Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...

Findings that evolocumab significantly reduced the risk of major adverse CV events in adults at high CV risk without prior heart attack or stroke vs placebo. Topline data were announced from a phase 3 ...

Please provide your email address to receive an email when new articles are posted on . Evolocumab lowered risk for major adverse CV events in a primary prevention population. Evolocumab is the first ...

Previously, Repatha was indicated to reduce the risk of MACE in patients with established cardiovascular disease. The Food and Drug Administration (FDA) has expanded the approval of Repatha ® ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...